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Objectives: To evaluate the short-term and long-term
prognostic impacts of acute phase coronary collaterals
to occluded infarct-related arteries (IRA) after
ST-elevation myocardial infarction (STEMI) in the
percutaneous coronary intervention (PCI) era.
Design: A prospective observational study.
Setting: Osaka Acute Coronary Insufficiency Study
(OACIS) in Japan.
Participants: 3340 patients with STEMI from the
OACIS database who were admitted to hospitals within
24 hours from the onset and who had a completely
occluded IRA.
Interventions: Patients were divided into 4 groups
according to the Rentrop collateral score (RCS) by
angiography on admission (RCS-0, no visible
collaterals; RCS-1, collaterals without IRA filling;
RCS-2, collaterals with partial IRA filling; and RCS-3,
collaterals with complete IRA filling).
Primary outcome measures: In-hospital and 5-year
mortality.
Results: Patients with RCS-0/3 were older than patients
with RCS-1/2, and the prevalence of previous myocardial
infarction was highest in patients with RCS-3. Median
peak creatinine phosphokinase levels decreased as RCS
increases (p<0.001), suggesting the acute
cardioprotective effects of collaterals. Although RCS-1
and RCS-2 collaterals were associated with better in-
hospital mortality (adjusted OR 0.48, p=0.046 and 0.38,
p=0.010 for RCS-1 and RCS-2, respectively) and 5-year
mortality (adjusted HR 0.53, p=0.004 and 0.46, p<0.001
for RCS-1 and RCS-2, respectively) as compared with R-
0, presence of RCS-3 collaterals was not associated with
improved in-hospital (adjusted OR 1.35, p=0.331) and 5-
year mortality (adjusted HR 0.98, p=0.920), possibly
because worse clinical profiles in patients with RCS-3
may mask mortality benefit of coronary collaterals.
Conclusions: Presence of acute phase coronary
collaterals such as RCS-1 and RCS-2 were associated
with better in-hospital and 5-year mortality after STEMI
in the contemporary PCI era.
INTRODUCTION
Coronary collaterals provide an alternative
source of blood supply to the ischaemic myo-
cardium.1–3 In patients with acute myocardial
infarction (AMI), collaterals to the infarct-
related arteries (IRA) are angiographically
observed in ∼40%,4 providing myocardial
protective effects such as improved func-
tional recovery,5 infarct size reduction,6 7 pre-
vention of no-reflow phenomenon8 or
prevention of ventricular aneurysm forma-
tion.9 Furthermore, coronary collaterals that
develop after the convalescent stage of AMI
were associated with prevention of subse-
quent ventricular remodelling.10 However,
some controversies have arisen regarding the
long-term beneficial impacts of coronary
Strengths and limitations of this study
▪ Our study has one of the largest study popula-
tions published until now, which allowed us to
evaluate the impact of coronary collaterals
among four Rentrop collateral categories.
▪ We evaluated the impact of coronary collaterals
on both in-hospital and 5-year mortality.
▪ There may be a selection bias because we only
focused on patients who visited hospitals within
24 hours from the onset and who underwent
emergent coronary angiography, and it is not clear
whether identical conclusions can be drawn for all
patients with ST-elevation myocardial infarction.
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collaterals in patients with AMI in the contemporary per-
cutaneous coronary intervention (PCI) era.11–18
Recently, many large-scale studies and their meta-analysis
revealed no association between coronary collaterals and
long-term mortality after AMI.13–17 One of the possible
reasons for this discrepancy is that the definition of sig-
nificant collaterals differed among the studies. For
example, minimal collaterals such as Rentrop grade 1
collaterals were sometimes classified as non-significant
collaterals. In addition, several studies did not exclude
patients with patent IRA. In such studies, interpretation
of the results were complicated and difficult because
antegrade flow of IRA was likely to have counteracted
with coronary collateral flow resulting in underestima-
tion of collateral flow grades.13–17 Thus, comprehensive
analyses in a large-scale cohort are now warranted so
that investigators can evaluate the cardioprotective
impacts of coronary collaterals in detail by selecting
patients with completely occluded IRA.
In the present study, we sought to investigate the impacts
of acute phase coronary collaterals on in-hospital and
5-year mortality enrolling 3340 patients with ST-elevation
myocardial infarction (STEMI) with completely occluded
IRA from the database of the Osaka Acute Coronary
Insufficiency Study (OACIS), a prospective multicentre
observational registry of patients with AMI in Japan.4 19
METHODS
Study population
We used the OACIS database to investigate the prognos-
tic impacts of acute phase coronary collaterals after
STEMI. The OACIS is a prospective, multicentre obser-
vational study designed to collect and analyse demo-
graphic, procedural and outcome data in patients with
AMI at 25 collaborating hospitals with cardiac emer-
gency units. All the study participants were informed
about data collection, blood sampling and genotyping,
and provided written informed consent. The diagnosis
of AMI was made on the basis of the WHO criteria,
which required at least two of the following three criteria
to be met: (1) clinical history of central chest pressure,
pain or tightness lasting >30 min; (2) ST segment eleva-
tion >0.1 mV in at least one standard and (3) a rise in
serum creatinine phosphokinase concentration to more
than twice the normal laboratory value. All the collabor-
ating hospitals were encouraged to enrol consecutive
patients with AMI. We prospectively collected data by
research cardiologists and trained research nurses using
a specific reporting form, and the variables presented in
Tables were extracted from the OACIS registry database
in this study. The OACIS started in April 1998, and there
were 8351 patients with STEMI as possible candidates
for this study during the study period (figure 1). It is
registered with the University Hospital Medical Information
Network Clinical Trials Registry (UMIN-CTR) in Japan
(ID: UMIN000004575), and details are described
elsewhere.4 19
This study included 3340 consecutive patients with
STEMI who were registered with the OACIS between
1998 and 2010 and fulfilled the following criteria: (1)
who underwent emergency coronary angiography within
24 hours after the onset, (2) complete occlusion of the
IRA which means thrombolysis in myocardial infarction
Figure 1 Patient selection flow. OACIS, Osaka Acute Coronary Insufficiency Study and STEMI, ST-elevation myocardial
infarction.
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Table 1 Patient background
Parameter Overall (n=3340) RCS-0 (n=2040) RCS-1 (n=530) RCS-2 (n=522) RCS-3 (n=248) p Value
Age, years 65 (57–73) 66 (57–74) 64 (55–71) 63 (55–71) 66 (57–74) <0.001
Male, % 76.9 75.8 80.0 77.6 78.2 0.197
Onset to admission, hour 2.4 (1.1–5.5) 2.3 (1.0–5.0) 2.3 (1.2–5.5) 3.0 (1.5–6.7) 3.0 (1.3–7.4) <0.001
Coronary risk factor
Diabetes, % 31.6 31.0 31.7 32.3 34.6 0.705
Hypertension, % 58.1 59.1 58.4 53.5 59.5 0.147
Dyslipidaemia, % 44.2 40.8 50.4 47.6 52.1 <0.001
Smoking, % 65.3 63.7 68.7 70.4 59.8 0.003
Previous MI, % 11.0 10.0 9.2 14.3 16.3 <0.001
Angina pectoris, % 20.7 17.6 22.8 25.9 31.1 <0.001
KILLIP classification 0.113
Class 1 82.0 80.9 83.2 84.8 82.8
Class 2 9.3 9.4 10.6 8.0 8.0
Class 3 2.5 2.4 2.1 2.9 2.5
Class 4 6.2 7.2 4.1 4.3 6.7
Laboratory data
Peak CPK, IU/L 2957 (1637–5030) 3225 (1722–5390) 3074 (1895–4915) 2514 (1449–4218) 2277 (1093–4180) <0.001
CAG findings
Culprit vessel <0.001
Left main trunk, % 1.8 1.7 1.3 1.9 3.3
LAD, % 44.0 42.7 48.3 45.2 42.7
Diagonal branch, % 2.4 3.1 1.0 1.2 2.8
RCA, % 41.5 40.1 43.5 44.8 41.9
LCx, % 10.2 12.4 5.5 6.7 9.3
Graft, % 0.1 0.0 0.4 0.2 0.0
Multivessel disease, % 35.1 34.3 29.5 35.6 53.7 <0.001
Emergency PCI, % 96.8 96.4 98.5 97.5 95.6 0.042
Final TIMI 3, % 85.8 84.9 85.4 87.8 89.6 0.127
CABG, % 1.7 1.6 1.2 1.7 3.7 0.064
Medication at discharge
ACEI, % 55.3 53.5 56.8 62.4 50.9 0.002
ARB, % 23.8 24.1 25.8 18.7 27.7 0.016
β-Blocker, % 48.7 49.0 50.3 45.0 51.3 0.271
Ca-blocker, % 16.8 17.9 15.0 15.3 15.6 0.297
Statin, % 41.8 40.9 42.0 42.0 47.3 0.334
Diuretics, % 29.0 29.7 28.8 26.9 28.6 0.664
Categorical variables are presented as percentage and continuous variables are presented as the median (25–75 percentiles).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CAG, coronary angiography; CPK, creatine kinase; LAD, left anterior descending artery; LCx, left
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(TIMI) flow grade 0, and (3) angiographic collateral
flow was evaluated using the Rentrop collateral score
(RCS) (figure 1).20 21 That is, RCS-0 indicates no visible
coronary collaterals; RCS-1, coronary collaterals without
IRA filling; RCS-2, coronary collaterals with partial IRA
filling; and RCS-3, collaterals with complete IRA filling.21
The authors had full access to the data and take
responsibility for their integrity. All authors have read
and agree to the manuscript as written.
Statistical analysis
Categorical variables were compared by the χ2 test, and
continuous variables were compared by the Kruskal-
Wallis test. The impacts of coronary collaterals on
in-hospital and 5-year mortality were assessed as ORs
and their 95% CIs with a logistic regression analysis,
and HRs and 95% CI with Cox regression analysis,
respectively. To reduce the confounding effects of varia-
tions in patient backgrounds, multivariable analyses were
employed where covariates were described in the foot-
note of each table. The Kaplan-Meier method was used
to estimate event rates, and the differences between RCS
grades were assessed by the log-rank tests. To exclude
the influence of stenosis of the supply artery and evalu-
ate the impacts of coronary collaterals appropriately, the
impacts of in-hospital and 5-year mortality were also eval-
uated in patients with single vessel disease of the main
coronary arteries (left anterior descending, left circum-
flex and right coronary arteries) without previous MI as
a subgroup analysis. Predictors of development of collat-
erals were assessed using univariable and multivariable
logistic regression analysis. Missing data were not com-
plemented, and patients with missing data were
Table 2 Predictors of development of collaterals
Univariable Multivariable (stepwise)
OR (95% CI) p Value adjusted OR (95% CI) p Value
Age, per 10 years 0.87 (0.82 to 0.92) <0.001 0.85 (0.79 to 0.91) <0.001
Male, % 1.18 (0.99 to 1.40) 0.052 – –
Onset to admission, hour 1.03 (1.02 to 1.04) <0.001 1.04 (1.02 to 1.05) <0.001
Coronary risk factor
Diabetes 1.07 (0.92 to 1.24) 0.390 – –
Hypertension 0.91 (0.78 to 1.05) 0.174 0.87 (0.74 to 1.02) 0.081
Dyslipidaemia 1.43 (1.24 to 1.65) <0.001 1.31 (1.12 to 1.53) <0.001
Smoking 1.19 (1.03 to 1.38) 0.020 – –
Previous MI 1.30 (1.04 to 1.62) 0.021 1.20 (0.93 to 1.54) 0.155
Angina pectoris 1.61 (1.36 to 1.91) <0.001 1.61 (1.34 to 1.94) <0.001
Culprit vessel
LCx 1 reference 1 reference
LAD 1.99 (1.53 to 2.60) <0.001 2.18 (1.64 to 2.92) <0.001
RCA 2.01 (1.55 to 2.64) <0.001 2.14 (1.61 to 2.87) <0.001
Other 1.36 (0.88 to 2.08) 0.158 1.58 (0.98 to 2.52) 0.059
Multivessel disease 1.11 (0.95 to 1.28) 0.179 1.15 (0.97 to 1.35) 0.103
Collaterals were divided into 2 variables (absent=RCS 0 or present=RCS 1–3).
Multivariable model was selected with stepwise method based on Akaike Information Criteria. Same results were obtained with decrease/
increase and increase/decrease stepwise models.
LAD, left anterior descending artery; LCx, left circumflex artery; RCA, right coronary artery.
Table 3 Impact of coronary collaterals on in-hospital
mortality
All study population (n=3340)
OR 95% CI p Value
Univariable
Rentrop 0 1 – reference
Rentrop 1 0.54 0.33 to 0.82 0.006
Rentrop 2 0.47 0.28 to 0.74 0.002
Rentrop 3 1.27 0.79 to 1.95 0.303
Multivariable
Rentrop 0 1 – reference
Rentrop 1 0.48 0.22 to 0.94 0.046
Rentrop 2 0.38 0.17 to 0.76 0.010
Rentrop 3 1.35 0.72 to 2.40 0.331
Single vessel disease without previous myocardial
infarction (n=1880)
OR 95% CI p Value
Univariable
Rentrop 0 1 – reference
Rentrop 1 0.59 0.28 to 1.12 0.131
Rentrop 2 0.33 0.11 to 0.76 0.019
Rentrop 3 0.20 0.03 to 1.49 0.118
Multivariable
Rentrop 0 1 – reference
Rentrop 1 0.60 0.20 to 1.5 0.318
Rentrop 2 0.29 0.05 to 1.03 0.104
Rentrop 3 <0.01 <0.01 to >10.0 0.987
Impact of coronary collaterals on in-hospital mortality was
estimated by univariable and multivariable logistic regression
analysis with Rentrop 0 serving as a reference. Age, gender,
onset to admission time, coronary risk factors (diabetes,
hypertension, dyslipidaemia, smoking, previous myocardial
infarction and angina pectoris), culprit vessel, multivessel disease
and emergency percutaneous coronary intervention were used as
covariates in a multivariable model.
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automatically excluded in the multivariable analyses.
Statistical significance was set as p<0.05. All statistical
analyses were performed using R software packages
V.3.2.1 for Mac (R Development Core Team).
RESULTS
Baseline characteristics and determinants of collaterals
Patient characteristics, number of missing data and predic-
tors of coronary collaterals are summarised in table 1,
online supplementary table S1 and table 2, respectively. In
general, patient backgrounds were significantly different
among RCS grades in age, onset to admission hour, dyslipi-
daemia, previous MI, angina pectoris, culprit vessel, multi-
vessel disease, emergency PCI, prescription rate of ACE
inhibitors at discharge and angiotensin receptor blocker.
In addition, median peak creatinine phosphokinase levels
decreased as RCS increases (table 1).
Multivariable logistic regression analysis revealed that
younger age, longer time from the onset to admission,
dyslipidaemia, history of angina pectoris, left anterior
descending artery, right coronary artery and presence of
multivessel disease were associated with presence of
collaterals in this study (table 2).
Impacts of coronary collaterals on in-hospital mortality
As shown in table 3, figure 2 and online supplementary
figure S1, in-hospital mortalities were significantly lower
in the RCS-1 and RCS-2 groups than in the RCS-0
group, whereas it was higher in the RCS-3 group than in
the RCS-0 group. However, if we analyse the data only in
patients with single vessel disease without previous MI,
in-hospital mortality decreases as RCS grade increases
(p=0.018). In multivariable logistic regression analysis,
adjusted OR for in-hospital mortality were 0.48 (95% CI
0.22 to 0.94, p=0.046), 0.38 (0.17 to 0.76, p=0.010) and
1.35 (0.72 to 2.40, p=0.331) in the RCS-1, RCS-2 and
RCS-3 groups, respectively.
Impacts of coronary collaterals on 5-year mortality
During a median follow-up duration of 1691 days (quar-
tile 714–1824) from STEMI onset, 418 events occurred
(306 in RCS-0, 39 in RCS-1, 38 in RCS-2 and 35 in
RCS-3). Kaplan-Meier survival estimates are shown in
figure 3. Patients with RCS-1 and RCS-2 collaterals
showed significantly better 5-year survival than patients
without coronary collaterals (RCS-0) or patients with
RCS-3 collaterals (p<0.001). On the other hand, in a
subgroup analysis, RCS-3 collaterals seemed to be asso-
ciated with better survival in patients with single vessel
disease without previous MI. In multivariable Cox regres-
sion analysis, adjusted HR for 5-year mortality were 0.53
(95% CI 0.34 to 0.82, p=0.004), 0.46 (0.30 to 0.70,
p<0.001) and 0.98 (0.65 to 1.48, p=0.920) in the RCS-1,
RCS-2 and RCS-3 groups, respectively (table 4). These
Figure 3 Kaplan-Meier survival
estimates in (A) an all study
population and (B) a subgroup of
single vessel disease of main
coronary arteries without previous
myocardial infarction. Numbers at
risk are summarised below the
figure. RCS, Rentrop collateral
score.
Figure 2 In-hospital mortality in
(A) an all study population and
(B) a subgroup of single vessel
disease of main coronary arteries
without previous myocardial
infarction. RCS, Rentrop collateral
score.
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trends were also suggested in all subgroups with excep-
tions in female patients and patients with single vessel
disease where RCS-3 tended to impact favourably on
5-year mortality as compared to other subgroups
(figure 4).
DISCUSSION
In this study, we investigated the impacts of acute phase
coronary collaterals on in-hospital and long-term
(5-year) mortality after STEMI in the contemporary PCI
era enrolling 3340 patients with an occluded IRA. This
study is one of the largest studies investigating the prog-
nostic impacts of coronary collaterals published until
now.16 We revealed that RCS-1 and RCS-2 collaterals
were associated with better in-hospital mortality
(adjusted OR of RCS-1 is 0.48 with p=0.046, and RCS-2
is 0.38 with p=0.010) and 5-year mortality (adjusted HR
of RCS-1 is 0.53 with p=0.004, and RCS-2 is 0.46 with
p<0.001) as compared with RCS-0, whereas presence of
RCS-3 collaterals were not associated with improved
in-hospital (p=0.331) and 5-year mortality (p=0.920).
Since subgroup analysis of single vessel disease without
the previous MI population showed that in-hospital
mortality and 5-year mortality tend to decrease as RCS
grade increases (figures 2 and 3), we hypothesised that
the cardioprotective impact of coronary collaterals
would increase along with an increments of angiographi-
cal collateral filling (RCS-0 to RCS-3), but that worse
clinical profiles in patients with RCS-3 may have masked
the mortality benefit of coronary collaterals (table 1).
Our results of the acute phase cardioprotective effect
and determinants of the presence of coronary collaterals
were consistent with previously published data. For
example median peak creatinine phosphokinase levels
decreased as RCS increases (p<0.001) in this study, sug-
gesting the acute cardioprotective effects of acute phase
coronary collaterals (table 1).6 7 12 In fact, in-hospital
mortality decreases as RCS grade increases in patients
with single vessel disease without previous MI. This is
consistent with the previously published data which sug-
gested the association between presence of coronary col-
laterals and lower in-hospital mortality.11 Determinants
of the presence of coronary collaterals in this study were
younger age, longer time from the onset to admission,
clinical history of angina pectoris, culprit vessel and pres-
ence of multivessel disease, which were also consistent
with the previously published data.1 4 11 13 14
Furthermore, we believe that our data gave us new
insights into the impacts of acute phase coronary collat-
erals in patients with STEMI. First, the presence of
angiographically minimal coronary collaterals, defined
as RCS-1, was even associated with better in-hospital and
5-year mortalities as compared with the absence of cor-
onary collaterals (RCS-0). Thus, it is suggested that clas-
sifying patients with RCS-0 and RCS-1 together as a
non-significant collateral group was inappropriate to
assess the impacts of coronary collaterals, although
many previous studies have investigated impacts of cor-
onary collaterals thus.12 14 16 The second important
finding of our study was that angiographically significant
coronary collaterals (RCS-3) were not associated with
better in-hospital and 5-year mortalities in the overall
study population. However, since subgroup analysis of
single vessel disease without previous MI revealed that
RCS-3 was associated with the lowest in-hospital mortality
and better 5-year mortality (figures 2B and 3B), it is con-
ceivable that worse clinical profiles in patients with
RCS-3 masked the mortality benefit of RCS-3 coronary
collaterals. Thus, our observations clearly demonstrated
that impacts of RCS-0, RCS-1, RCS-2 and RCS-3 should
be evaluated separately to accurately assess the prognos-
tic impacts of coronary collaterals, under the consider-
ation of the patient’s clinical background.
Recently, therapeutic promotion of coronary collateral
growth is considered as a valuable treatment strategy for
ischaemic heart disease and potential benefits of this
therapy have been intensively investigated.22–24 The
rationale of this approach is mainly based on the short-
term beneficial impact of coronary collaterals.22 23 In
addition to this, our study also suggested the long-term
benefits of coronary collaterals in patients with STEMI,
Table 4 Impact of coronary collaterals on 5-year mortality
All study population (n=3340)
HR 95% CI p Value
Univariable
Rentrop 0 1 – reference
Rentrop 1 0.47 0.34 to 0.66 <0.001
Rentrop 2 0.46 0.33 to 0.64 <0.001
Rentrop 3 0.94 0.66 to 1.33 0.714
Multivariable
Rentrop 0 1 – reference
Rentrop 1 0.53 0.34 to 0.82 0.004
Rentrop 2 0.46 0.30 to 0.70 <0.001
Rentrop 3 0.98 0.65 to 1.48 0.920
Single vessel disease without previous myocardial
infarction (n=1880)
HR 95% CI p Value
Univariable
Rentrop 0 1 – reference
Rentrop 1 0.45 0.27 to 0.74 0.002
Rentrop 2 0.35 0.20 to 0.64 <0.001
Rentrop 3 0.45 0.18 to 1.09 0.077
Multivariable
Rentrop 0 1 – reference
Rentrop 1 0.49 0.26 to 0.91 0.025
Rentrop 2 0.37 0.17 to 0.80 0.011
Rentrop 3 0.56 0.21 to 1.55 0.267
Impact of coronary collaterals on 5-year mortality was estimated
by univariable and multivariable Cox regression analysis with
Rentrop 0 serving as a reference. Age, gender, coronary risk
factors (diabetes, hypertension, dyslipidaemia, smoking, previous
myocardial infarction and angina pectoris), culprit vessel,
multivessel disease, emergency percutaneous coronary
intervention, ACE inhibitors, angiotensin receptor blocker,
β-blocker, calcium-blocker, statin and diuretic usage were used as
covariates in a multivariable model.
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which are consistent with the recent evidence demon-
strating the long-term favourable impact of coronary col-
laterals in stable coronary artery disease.16 25 Thus, we
believe that our result may make the clinical implication
such as therapeutic angiogenesis more anticipating.
Study limitations
There are several limitations that warrant mention. First,
this study included only patients who were able to visit
hospitals within 24 hours after STEMI onset, and who
could undergo emergent coronary angiography which
revealed complete occlusion of IRA (TIMI grade 0);
therefore, there could be a selection bias in this study
and it is not clear whether identical conclusions can be
drawn for all patients with STEMI. However, we specu-
lated that this process made it possible to assess the
impact of coronary collaterals more accurately than
enrolling all study population. Second, the study end
point was set as all-cause mortality and one-third causes
of all death events were not clearly determined. Third,
collateral functionalities were not assessed with flow
wires because that was not a prespecified purpose of the
OACIS registry. These might lead to biased results. Thus,
caution is required in interpretation of our results.
CONCLUSIONS
Presence of acute phase coronary collaterals was asso-
ciated with better in-hospital and 5-year mortality after
STEMI in the contemporary PCI era, if its angiographical
coronary filling was minimal or moderate. However, it
should be underlined that patients with angiographically
significant collaterals (RCS-3) were characterised by
worse baseline clinical backgrounds, and thus not neces-
sarily associated with better survival. The benefit of
acute phase coronary collaterals should be evaluated in
combination with patient clinical backgrounds.
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